Real-world derived weight-based levothyroxine doses to achieve optimal thyrotropin target in different degrees of autoimmune hypothyroidism

The Egyptian Journal of Internal Medicine

Table 2 Comparison between the different studied groups according to different parameters

	Group 1 (n = 87)	Group 2 (n = 95)	Group 3 (n = 75)	Group 4 (n = 91)	p
TSH
Mean ± SD	1.5 ± 0.51	1.5 ± 0.49	1.2 ± 0.50	1.4 ± 0.50	0.001^*
Median (min.–max.)	1.5 (0.41–2.5)	1.5 (0.36–2.4)	1.1 (0.37–2.3)	1.5 (0.32–2.5)	0.001^*
Sig. bet. grps	p₁ = 0.686, p₂ < 0.001^, p₃ = 0.051, p₄ = 0.001^, p₅ = 0.113, p₆ = 0.063
Daily levothyroxine dose
Mean ± SD	83.4 ± 24.6	97.7 ± 24.7	116.1 ± 31.7	106.5 ± 32.1	< 0.001^*
Median (min.–max.)	78 (50–165)	100 (50–200)	114 (43–250)	100 (53–215)	< 0.001^*
Sig. bet. grps	p₁ < 0.001^, p₂ < 0.001^, p₃ < 0.001^, p₄ < 0.001^, p₅ = 0.162, p₆ = 0.010^*
L-T4 dose (µg/kg/day)
Mean ± SD	1 ± 0.25	1.2 ± 0.26	1.4 ± 0.29	1.2 ± 0.31	< 0.001^*
Median (min.–max.)	0.99 (0.48–1.7)	1.1 (0.68–2.2)	1.4 (0.61–2.5)	1.2 (0.60–1.3)	< 0.001^*
Sig. bet. grps	p₁ < 0.001^, p₂ < 0.001^, p₃ < 0.001^, p₄ < 0.001^, p₅ = 0.150, p₆ < 0.001^*
Duration of reported dose (months)
Mean ± SD	27.3 ± 19.8	25.8 ± 17.7	27.1 ± 18.3	25.9 ± 17.8	0.949
Median (min.–max.)	20 (6–95)	22 (6–75)	23 (6–96)	21 (6–90)	0.949

Group 1 mild subclinical hypothyroidism, Group 2 severe subclinical hypothyroidism, Group 3 overt hypothyroidism, Group 4 hypothyroidism unknown
SD standard deviation
p: p value for comparing between the studied groups
p₁: p value for comparing between Group 1 and Group 2
p₂: p value for comparing between Group 1 and Group 3
p₃: p value for comparing between Group 1 and Group 4
p₄: p value for comparing between Group 2 and Group 3
p₅: p value for comparing between Group 2 and Group 4
p₆: p value for comparing between Group 3 and Group 4
^*Statistically significant at p ≤ 0.05